Repligen [RGEN] vs Stevanato [STVN] Detailed Stock Comparison
Repligen
NASDAQ
Loading...
Stevanato
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Repligen wins in 4 metrics, Stevanato wins in 15 metrics, with 0 ties. Stevanato appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Repligen | Stevanato | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 511.11 | 38.58 | Stevanato |
| Price-to-Book Ratio | 3.40 | 4.29 | Repligen |
| Debt-to-Equity Ratio | 33.28 | 29.80 | Stevanato |
| PEG Ratio | 3.19 | 1.03 | Stevanato |
| EV/EBITDA | 55.34 | 25.44 | Stevanato |
| Profit Margin (TTM) | -2.05% | 11.75% | Stevanato |
| Operating Margin (TTM) | 5.28% | 15.03% | Stevanato |
| EBITDA Margin (TTM) | 5.28% | 15.03% | Stevanato |
| Return on Equity | -0.68% | 9.89% | Stevanato |
| Return on Assets (TTM) | 1.13% | 5.20% | Stevanato |
| Free Cash Flow (TTM) | $142.49M | $-184.86M | Repligen |
| 1-Year Return | -19.66% | 0.50% | Stevanato |
| Price-to-Sales Ratio (TTM) | 10.42 | 5.24 | Stevanato |
| Enterprise Value | $7.00B | $7.60B | Stevanato |
| EV/Revenue Ratio | 10.38 | 5.67 | Stevanato |
| Gross Profit Margin (TTM) | 49.98% | 28.06% | Repligen |
| Revenue per Share (TTM) | $12 | $4 | Repligen |
| Earnings per Share (Diluted) | $-0.25 | $0.57 | Stevanato |
| Beta (Stock Volatility) | 1.05 | 0.55 | Stevanato |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Repligen vs Stevanato Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Repligen | -2.83% | -2.27% | -0.39% | -1.04% | -24.90% | -15.23% |
| Stevanato | -2.79% | -2.66% | -17.05% | -3.72% | 5.37% | -1.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Repligen | -19.66% | -42.35% | -16.60% | 266.34% | 3,508.93% | 3,025.26% |
| Stevanato | 0.50% | 33.84% | 11.79% | 11.79% | 11.79% | 11.79% |
Performance & Financial Health Analysis: Repligen vs Stevanato
| Metric | RGEN | STVN |
|---|---|---|
| Market Information | ||
| Market Cap | $7.02B | $6.00B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 697,970 | 295,683 |
| 90 Day Avg. Volume | 934,717 | 365,188 |
| Last Close | $121.26 | $21.99 |
| 52 Week Range | $102.97 - $182.52 | $17.12 - $28.00 |
| % from 52W High | -33.56% | -21.46% |
| All-Time High | $327.32 (Sep 20, 2021) | $36.30 (Aug 07, 2023) |
| % from All-Time High | -62.95% | -39.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.08% |
| Quarterly Earnings Growth | 1.60% | 0.44% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | 0.12% |
| Operating Margin (TTM) | 0.05% | 0.15% |
| Return on Equity (TTM) | -0.01% | 0.10% |
| Debt to Equity (MRQ) | 33.28 | 29.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $36.65 | $5.12 |
| Cash per Share (MRQ) | $12.60 | $0.38 |
| Operating Cash Flow (TTM) | $132.11M | $242.13M |
| Levered Free Cash Flow (TTM) | $155.35M | $-83,845,395 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Repligen vs Stevanato
| Metric | RGEN | STVN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 511.11 | 38.58 |
| Forward P/E | 70.11 | 36.65 |
| PEG Ratio | 3.19 | 1.03 |
| Price to Sales (TTM) | 10.42 | 5.24 |
| Price to Book (MRQ) | 3.40 | 4.29 |
| Market Capitalization | ||
| Market Capitalization | $7.02B | $6.00B |
| Enterprise Value | $7.00B | $7.60B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.38 | 5.67 |
| Enterprise to EBITDA | 55.34 | 25.44 |
| Risk & Other Metrics | ||
| Beta | 1.05 | 0.55 |
| Book Value per Share (MRQ) | $36.65 | $5.12 |
Financial Statements Comparison: Repligen vs Stevanato
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGEN | STVN |
|---|---|---|
| Revenue/Sales | $182.37M | $328.07M |
| Cost of Goods Sold | $91.22M | $236.00M |
| Gross Profit | $91.14M | $92.07M |
| Research & Development | $13.96M | $7.08M |
| Operating Income (EBIT) | $5.96M | $48.46M |
| EBITDA | $33.81M | $73.69M |
| Pre-Tax Income | $18.22M | $45.82M |
| Income Tax | $3.35M | $11.02M |
| Net Income (Profit) | $14.87M | $34.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGEN | STVN |
|---|---|---|
| Cash & Equivalents | $697.23M | $110.32M |
| Total Current Assets | $1.03B | $1.01B |
| Total Current Liabilities | $152.00M | $564.21M |
| Long-Term Debt | $668.54M | $400.21M |
| Total Shareholders Equity | $1.99B | $1.64B |
| Retained Earnings | $413.18M | N/A |
| Property, Plant & Equipment | $265.24M | $131.42M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGEN | STVN |
|---|---|---|
| Operating Cash Flow | $14.16M | $56.70M |
| Capital Expenditures | $-3.52M | $-67.08M |
| Free Cash Flow | $10.58M | $-17.99M |
| Debt Repayment | N/A | $-33.73M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RGEN | STVN |
|---|---|---|
| Shares Short | 3.64M | 2.03M |
| Short Ratio | 3.98 | 6.60 |
| Short % of Float | 0.09% | 0.04% |
| Average Daily Volume (10 Day) | 697,970 | 295,683 |
| Average Daily Volume (90 Day) | 934,717 | 365,188 |
| Shares Outstanding | 56.09M | 319.71M |
| Float Shares | 52.66M | 48.89M |
| % Held by Insiders | 0.06% | 0.02% |
| % Held by Institutions | 1.05% | 1.13% |
Dividend Analysis & Yield Comparison: Repligen vs Stevanato
| Metric | RGEN | STVN |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.04 |
| 3-Year Avg Dividend Yield | N/A | 0.26% |
| 3-Year Total Dividends | N/A | $0.12 |
| Ex-Dividend Date | N/A | Jun 04, 2024 |